David Jayne
University of Cambridge
Internal medicineSurgeryPathologyDermatologyRandomized controlled trialIntensive care medicineRheumatologyImmunologyAnti-neutrophil cytoplasmic antibodyVasculitisCyclophosphamideSystemic vasculitisMicroscopic polyangiitisDiseaseRituximabGranulomatosis with polyangiitisANCA-Associated VasculitisClinical trialMedicineGastroenterology
Publications 419
#1Joanna Tieu (University of Cambridge)H-Index: 3
#2Rona M Smith (University of Cambridge)H-Index: 15
Last. David Jayne (University of Cambridge)H-Index: 98
view all 8 authors...
Objective To evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement therapy. Methods Patients received RTX for autoimmune disease between 2003 and 2012 with immunoglobulin G (IgG) <7g/L were included in this retrospective series. Hypogammaglobulinemia was classified by nadir IgG subgroups of 5 to <7g/L (mild), 3 to <5g/L (moderate) and <3g...
3 CitationsSource
#1Annette Bruchfeld (Linköping University)H-Index: 31
#2Andreas Kronbichler (University of Cambridge)H-Index: 24
Last. Wladimir Szpirt (UCPH: University of Copenhagen)H-Index: 9
view all 8 authors...
1 CitationsSource
#1Tania Gudu (Cambridge University Hospitals NHS Foundation Trust)
#2Carmel Stober (Cambridge University Hospitals NHS Foundation Trust)
Last. Frances Hall (Cambridge University Hospitals NHS Foundation Trust)H-Index: 23
view all 9 authors...
1 CitationsSource
#1Salem AlmaaniH-Index: 8
#2Lynn A. Fussner (The Ohio State University Wexner Medical Center)
Last. David JayneH-Index: 98
view all 5 authors...
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The two major antigens targeted by ANCAs are leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). AAV can be classified into 3 categories based on patterns of clinical involvement: namely, granulomatosis with polyangiitis (G...
2 CitationsSource
#1David Jayne (University of Cambridge)H-Index: 98
In the absence of cures for multi-system inflammatory disease, therapies aim to dampen long-term inflammation, control symptoms and prevent tissue damage. Glucocorticoids (GC) are a key anti-inflammatory agent with a rapid mode of action and broad targeting of multiple pathways. However, GC toxicity causes organ damage affecting organ function and patient quality of life.1 Recent advances in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) treatments, include B-cell target...
#1Paul A. Brogan (Great Ormond Street Hospital for Children NHS Foundation Trust)H-Index: 47
#2Barbara Arch (University of Liverpool)H-Index: 4
Last. Despina Eleftheriou (GOSH: Great Ormond Street Hospital)H-Index: 24
view all 23 authors...
OBJECTIVE Cyclophosphamide (CYC) is used in clinical practice off-label for induction of remission of childhood polyarteritis nodosa (cPAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative: we explored their relative effectiveness in a randomised controlled trial (RCT). METHODS International, open-label, Bayesian, RCT investigating the relative effectiveness of MMF and CYC for remission induction in cPAN. Eleven newly-diagnosed patients were randomised (1:1) to MMF or intravenou...
1 CitationsSource
#1Matthew A Rutherford (Glas.: University of Glasgow)
#2Jennifer Scott (Trinity College, Dublin)H-Index: 4
Last. Ukivas
view all 17 authors...
OBJECTIVE: COVID-19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic vasculitis have an increased risk of serious infections and so may be at risk of severe outcomes following COVID-19. It is important to establish the risk factors for severe COVID-19 outcomes in these patients, including the impact of immunosuppressive therapies. METHODS: A multi-centre cohort was developed through the participation of centres affiliated with national UK and Irela...
7 CitationsSource
#1Mark McClure (University of Cambridge)H-Index: 3
#2Yajing Zhu (University of Cambridge)H-Index: 1
Last. Rachel B Jones (University of Cambridge)H-Index: 22
view all 10 authors...
OBJECTIVES Following a maintenance course of rituximab (RTX) for ANCA-associated vasculitis (AAV), relapses occur on cessation of therapy, and further dosing is considered. This study aimed to develop relapse and infection risk prediction models to help guide decision making regarding extended RTX maintenance therapy. METHODS Patients with a diagnosis of AAV who received 4-8 grams of RTX as maintenance treatment between 2002 and 2018 were included. Both induction and maintenance doses were inclu...
6 CitationsSource
#1David Jayne (University of Cambridge)H-Index: 98
The management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1 Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2.